U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,190.69
    +43.76 (+2.04%)
     
  • Crude Oil

    66.26
    +2.43 (+3.81%)
     
  • Gold

    1,696.40
    -4.30 (-0.25%)
     
  • Silver

    25.23
    -0.24 (-0.93%)
     
  • EUR/USD

    1.1922
    -0.0057 (-0.48%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3845
    -0.0049 (-0.35%)
     
  • USD/JPY

    108.3550
    +0.3790 (+0.35%)
     
  • BTC-USD

    49,369.28
    +1,558.43 (+3.26%)
     
  • CMC Crypto 200

    986.55
    +43.37 (+4.60%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Gilead forecasts 2021 growth, strong remdesivir COVID-19 sales

  • Oops!
    Something went wrong.
    Please try again later.
Vishwadha Chander and Deena Beasley
·2 min read
Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California
  • Oops!
    Something went wrong.
    Please try again later.

By Vishwadha Chander and Deena Beasley

(Reuters) - Gilead Sciences Inc on Thursday forecast its 2021 results above Wall Street estimates after posting a 26% rise in fourth-quarter 2020 revenue, driven by sales of its antiviral drug, remdesivir, which is used to treat COVID-19 patients.

Shares of Gilead were up 2.5% in extended trading.

Gilead said the COVID-19 pandemic continues to affect its sales, including its treatments for hepatitis C and HIV, due to fewer people going to their doctors. It expects a gradual recovery in underlying market dynamics starting the second quarter of this year.

Remdesivir, which is sold under the brand name Veklury, brought in $1.9 billion in the fourth quarter ended Dec. 31, above analysts' estimates of $1.34 billion. Excluding Veklury, Gilead said its quarterly sales fell 7%.

The company said remdesivir continues to be a critical tool during the COVID-19 pandemic, forecasting 2021 sales of up to $3 billion for the drug.

Gilead Chief Medical Officer Merdad Parsey said that unlike current COVID-19 vaccines and some other drugs, remdesivir does not target the spike proteins of the coronavirus, which are altered in some recently-identified, more transmissible variants of the virus.

"We have not so far seen mutations that would impact the efficacy of remdesivir," he said during a conference call.

Gilead said it continues to work on an inhaled version of the COVID-19 drug - which is given intravenously to hospitalized patients - but more clinical study is required.

For 2021, the California-based company projected an adjusted earnings range with a midpoint of $7.10 per share, on product sales with a midpoint of $24.4 billion, ahead of respective Wall Street estimates of $6.85 per share and $24.27 billion, according to IBES data from Refinitiv.

"We think the $7 number is higher than where investors were looking for and provides a good base to continue to grow," Jefferies analyst Michael Yee said in an email.

He said Gilead projected 2021 operating expenses at less than analysts have estimated.

The company's fourth-quarter revenue totaled $7.42 billion, beating the average analyst estimate of $7.33 billion. Adjusted quarterly earnings of $2.19 were ahead of Wall Street expectations of $2.15 per share.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D'Silva, Ramakrishnan M. and Karishma Singh)